GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Current Ratio

Apollon Formularies (AQSE:APOL) Current Ratio : 0.60 (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Apollon Formularies Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Apollon Formularies's current ratio for the quarter that ended in Jun. 2023 was 0.60.

Apollon Formularies has a current ratio of 0.60. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Apollon Formularies has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for Apollon Formularies's Current Ratio or its related term are showing as below:

AQSE:APOL' s Current Ratio Range Over the Past 10 Years
Min: 0.6   Med: 1.78   Max: 10.39
Current: 0.6

During the past 11 years, Apollon Formularies's highest Current Ratio was 10.39. The lowest was 0.60. And the median was 1.78.

AQSE:APOL's Current Ratio is ranked worse than
88.44% of 1073 companies
in the Drug Manufacturers industry
Industry Median: 1.88 vs AQSE:APOL: 0.60

Apollon Formularies Current Ratio Historical Data

The historical data trend for Apollon Formularies's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies Current Ratio Chart

Apollon Formularies Annual Data
Trend Jun10 Jun11 Dec12 Dec13 Dec14 Dec17 Dec18 Dec19 Dec20 Dec21
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.41 1.25 2.44 2.86 8.02

Apollon Formularies Semi-Annual Data
Jun11 Jun12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Jun23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.86 10.39 8.02 1.05 0.60

Competitive Comparison of Apollon Formularies's Current Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Apollon Formularies's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apollon Formularies's Current Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apollon Formularies's Current Ratio distribution charts can be found below:

* The bar in red indicates where Apollon Formularies's Current Ratio falls into.



Apollon Formularies Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Apollon Formularies's Current Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Current Ratio (A: Dec. 2021 )=Total Current Assets (A: Dec. 2021 )/Total Current Liabilities (A: Dec. 2021 )
=0.666/0.083
=8.02

Apollon Formularies's Current Ratio for the quarter that ended in Jun. 2023 is calculated as

Current Ratio (Q: Jun. 2023 )=Total Current Assets (Q: Jun. 2023 )/Total Current Liabilities (Q: Jun. 2023 )
=1.112/1.842
=0.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Apollon Formularies  (AQSE:APOL) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Apollon Formularies Current Ratio Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollon Formularies (AQSE:APOL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS
Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.

Apollon Formularies (AQSE:APOL) Headlines

From GuruFocus

Apollo Group: This Unloved Company Is Significantly Undervalued

By Matthew Dow Matthew Dow 05-09-2013

Update from FPA Capital - Seven Changes to Portfolio

By Sally Jones Sally Jones 07-14-2013

The Yacktman Focused Fund's Top Growth Stocks

By Dianne Tordillo Dianne Tordillo 01-25-2013

FPA Capital Fund new buys in Q2 2015

By Tiziano Frateschi Tiziano Frateschi 07-14-2015

FPA Capital Fund Comments on For-Profit Education Stocks

By Holly LaFon Holly LaFon 12-09-2015

FPA Capital Fund Comments on Apollo Education Group Inc

By Vera Yuan Vera Yuan 02-19-2015

5-Star Predictable Companies with Highest ROA

By Holly LaFon Holly LaFon 03-20-2012

FPA Capital Comments on Apollo Education

By Holly LaFon Holly LaFon 01-30-2017

Yacktman Funds Comments on Apollo Group

By Holly LaFon Holly LaFon 03-13-2013